Page last updated: 2024-11-12
4-hydroxyphenformin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-hydroxyphenformin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10013772 |
| SCHEMBL ID | 2739120 |
| SCHEMBL ID | 17777450 |
| MeSH ID | M0088834 |
Synonyms (13)
| Synonym |
|---|
| 4-hydroxyphenformin |
| 17426-94-7 |
| 1-(diaminomethylidene)-2-[2-(4-hydroxyphenyl)ethyl]guanidine |
| 4-hydroxyphenylethylbiguanide |
| p-hydroxy-beta-phenethylbiguanide |
| 4-hydroxyphenylethyldiguanide |
| imidodicarbonimidic diamide, n-(2-(4-hydroxyphenyl)ethyl)- |
| p-hydroxyphenylethylbiguanide |
| unii-a1u54nh73s |
| a1u54nh73s , |
| AKOS021356045 |
| SCHEMBL2739120 |
| SCHEMBL17777450 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Of the 141 subjects dosed with debrisoquin, 10 proved to be poor oxidizers, and of the 143 subjects dosed with phenformin, 11 were poor oxidizers." | ( Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Eichelbaum, M; Idle, JR; Oates, NS; Smith, RL; Woolhouse, NM, 1985) | 0.27 |
| " Although the urinary excretion of unchanged phenformin was greater in PM between 2 and 24 hr after dosing than in EM, excretion of 4-hydroxy-phenformin could not be detected in most samples collected from PM but was present in every sample from EM." | ( Influence of oxidation polymorphism on phenformin kinetics and dynamics. Idle, JR; Oates, NS; Shah, RR; Smith, RL, 1983) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||